Nicolas Frey
Overview
Explore the profile of Nicolas Frey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wunderlich M, Frey N, Amende-Wolf S, Hinrichs C, Balzer F, Poncette A
JMIR Med Inform
. 2024 Sep;
12:e58347.
PMID: 39250783
Background: In response to the high patient admission rates during the COVID-19 pandemic, provisional intensive care units (ICUs) were set up, equipped with temporary monitoring and alarm systems. We sought...
2.
Frey N, Haffer N, Vogelsang L, Sass J, Gatrio M, Thun S, et al.
Stud Health Technol Inform
. 2024 Sep;
317:152-159.
PMID: 39234718
Introduction: For an interoperable Intelligent Tutoring System (ITS), we used resources from Fast Healthcare Interoperability Resources (FHIR) and mapped learning content with Unified Medical Language System (UMLS) codes to enhance...
3.
Chiba F, Nowak A, Frey N, Klopfenstein S, Meyer-Eschenbach F, Poncette A
Stud Health Technol Inform
. 2024 Aug;
316:127-131.
PMID: 39176690
While the importance of Electronic Health Records (EHR) interoperability is widely recognised in the healthcare digitalisation context, its optimal governance structure remains controversial, requiring further research. Through the rapid literature...
4.
Frey N, Haffer N, Vogelsang L, Sass J, Thun S, Balzer F, et al.
Stud Health Technol Inform
. 2024 Aug;
316:1536-1537.
PMID: 39176497
Our novel Intelligent Tutoring System (ITS) architecture integrates HL7 Fast Healthcare Interoperability Resources (FHIR) for data exchange and Unified Medical Language System (UMLS) codes for content mapping.
5.
Marshall S, Ahamadi M, Chien J, Iwata D, Farkas P, Filipe A, et al.
Clin Pharmacol Ther
. 2023 Aug;
114(5):954-959.
PMID: 37534711
No abstract available.
6.
Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Silber Baumann H, et al.
Clin Pharmacokinet
. 2023 May;
62(6):891-904.
PMID: 37148485
Background And Objective: Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by insufficient levels of survival motor neuron (SMN) protein. Risdiplam (Evrysdi) increases SMN protein and is approved...
7.
Agha-Mir-Salim L, Mosch L, Klopfenstein S, Wunderlich M, Frey N, Poncette A, et al.
Stud Health Technol Inform
. 2022 May;
294:805-806.
PMID: 35612209
Routine medical care is to be transformed by the introduction of artificial intelligence (AI), requiring medical professionals to acquire a novel set of skills. We assessed the density of AI...
8.
Retout S, Gieschke R, Serafin D, Weber C, Frey N, Hofmann C
Clin Pharmacol Ther
. 2022 Jan;
111(4):857-866.
PMID: 35100444
Selecting the right dose is a significant challenge in designing clinical development programs, especially for slowly progressing diseases lacking predictive biomarkers of efficacy that may require long-term treatment to assess...
9.
Hsu J, Jaminion F, Guerini E, Balas B, Bordogna W, Morcos P, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Sep;
10(11):1357-1370.
PMID: 34547184
Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK-positive non-small cell lung cancer. Population pharmacokinetic (PK) models were developed for alectinib and its major active metabolite...
10.
Gonzalez-Sales M, Djebli N, Meneses-Lorente G, Buchheit V, Bonnefois G, Tremblay P, et al.
Cancer Chemother Pharmacol
. 2021 Sep;
88(6):997-1007.
PMID: 34536094
Purpose: Entrectinib (ROZLYTREK) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung...